{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:16:45Z","timestamp":1789759005338,"version":"4.0.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T00:00:00Z","timestamp":1610409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T00:00:00Z","timestamp":1610409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20ek0310014"],"award-info":[{"award-number":["JP20ek0310014"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cisplatin, one of the most active anticancer agents, is widely used in standard chemotherapy for various cancers. Cisplatin is more poorly tolerated than other chemotherapeutic drugs, and the main dose-limiting toxicity of cisplatin is its nephrotoxicity, which is dose-dependent. Although less toxic methods of cisplatin administration have been established, cisplatin-induced nephrotoxicity remains an unsolved problem. Megalin is an endocytic receptor expressed at the apical membrane of proximal tubules. We previously demonstrated that nephrotoxic drugs, including cisplatin, are reabsorbed through megalin and cause proximal tubular cell injury. We further found that cilastatin blocked the binding of cisplatin to megalin in vitro. In this study, we investigated whether cilastatin could reduce cisplatin-induced nephrotoxicity without influencing the antitumor effects of cisplatin. Nephrotoxicity was decreased or absent in mice treated with cisplatin and cilastatin, as determined by kidney injury molecule-1 staining and the blood urea nitrogen content. Combined with cilastatin, a twofold dose of cisplatin was used to successfully treat the mice, which enhanced the antitumor effects of cisplatin but reduced its nephrotoxicity. These findings suggest that we can increase the dose of cisplatin when combined with cilastatin and improve the outcome of cancer patients.<\/jats:p>","DOI":"10.1038\/s41598-020-80853-6","type":"journal-article","created":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T14:24:12Z","timestamp":1610461452000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Combination therapy of cisplatin with cilastatin enables an increased dose of cisplatin, enhancing its antitumor effect by suppression of nephrotoxicity"],"prefix":"10.1038","volume":"11","author":[{"given":"Masashi","family":"Arita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobumasa","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoji","family":"Kuwahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sawako","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miho","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyuki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Hokari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Ohtsubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Shoji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Nozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rie","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masachika","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyoshi","family":"Ohshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Kabasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihiro","family":"Hosojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Koya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,12]]},"reference":[{"key":"80853_CR1","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi, L. et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med. 378, 2078\u20132092. https:\/\/doi.org\/10.1056\/NEJMoa1801005 (2018).","journal-title":"N. Engl. J. Med."},{"key":"80853_CR2","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/s0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness, B. et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): A randomised, open-label, phase 3 study. Lancet 394, 1915\u20131928. https:\/\/doi.org\/10.1016\/s0140-6736(19)32591-7 (2019).","journal-title":"Lancet"},{"key":"80853_CR3","doi-asserted-by":"publisher","first-page":"937429","DOI":"10.1155\/2014\/937429","volume":"2014","author":"HE Liu","year":"2014","unstructured":"Liu, H. E. et al. Multiple analytical approaches demonstrate a complex relationship of genetic and nongenetic factors with cisplatin- and carboplatin-induced nephrotoxicity in lung cancer patients. Biomed. Res. Int. 2014, 937429. https:\/\/doi.org\/10.1155\/2014\/937429 (2014).","journal-title":"Biomed. Res. Int."},{"key":"80853_CR4","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1007\/s00204-012-0821-7","volume":"86","author":"NA de Santos","year":"2012","unstructured":"de Santos, N. A., Carvalhorodrigues, M. A., Martins, N. M. & de Santos, A. C. Cisplatin-induced nephrotoxicity and targets of nephroprotection: An update. Arch. Toxicol. 86, 1233\u20131250. https:\/\/doi.org\/10.1007\/s00204-012-0821-7 (2012).","journal-title":"Arch. Toxicol."},{"key":"80853_CR5","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s12885-016-2271-8","volume":"16","author":"K Sato","year":"2016","unstructured":"Sato, K. et al. Nephrotoxicity of cisplatin combination chemotherapy in thoracic malignancy patients with CKD risk factors. BMC Cancer 16, 222. https:\/\/doi.org\/10.1186\/s12885-016-2271-8 (2016).","journal-title":"BMC Cancer"},{"key":"80853_CR6","doi-asserted-by":"publisher","first-page":"9725","DOI":"10.1073\/pnas.91.21.9725","volume":"91","author":"A Saito","year":"1994","unstructured":"Saito, A., Pietromonaco, S., Loo, A. K. & Farquhar, M. G. Complete cloning and sequencing of rat gp330\/\"megalin,\" a distinctive member of the low density lipoprotein receptor gene family. Proc. Natl. Acad. Sci. USA. 91, 9725\u20139729. https:\/\/doi.org\/10.1073\/pnas.91.21.9725 (1994).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"80853_CR7","first-page":"349","volume":"66","author":"EI Christensen","year":"1995","unstructured":"Christensen, E. I. et al. Segmental distribution of the endocytosis receptor gp330 in renal proximal tubules. Eur. J. Cell Biol. 66, 349\u2013364 (1995).","journal-title":"Eur. J. Cell Biol."},{"key":"80853_CR8","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1681\/asn.2015020190","volume":"27","author":"S Kuwahara","year":"2016","unstructured":"Kuwahara, S. et al. Megalin-mediated tubuloglomerular alterations in high-fat diet-induced kidney disease. J. Am. Soc. Nephrol. 27, 1996\u20132008. https:\/\/doi.org\/10.1681\/asn.2015020190 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"80853_CR9","doi-asserted-by":"publisher","first-page":"F539","DOI":"10.1152\/ajprenal.1988.255.3.F539","volume":"255","author":"MS Paller","year":"1988","unstructured":"Paller, M. S. Hemoglobin- and myoglobin-induced acute renal failure in rats: Role of iron in nephrotoxicity. Am. J. Physiol. 255, F539-544. https:\/\/doi.org\/10.1152\/ajprenal.1988.255.3.F539 (1988).","journal-title":"Am. J. Physiol."},{"key":"80853_CR10","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1681\/ASN.2016060606","volume":"28","author":"Y Hori","year":"2017","unstructured":"Hori, Y. et al. Megalin blockade with cilastatin suppresses drug-induced nephrotoxicity. J. Am. Soc. Nephrol. 28, 1783\u20131791. https:\/\/doi.org\/10.1681\/ASN.2016060606 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"80853_CR11","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1124\/jpet.110.165779","volume":"334","author":"S Camano","year":"2010","unstructured":"Camano, S. et al. Cilastatin attenuates cisplatin-induced proximal tubular cell damage. J. Pharmacol. Exp. Ther. 334, 419\u2013429. https:\/\/doi.org\/10.1124\/jpet.110.165779 (2010).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"80853_CR12","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina, J. et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603\u2013607. https:\/\/doi.org\/10.1038\/nature11003 (2012).","journal-title":"Nature"},{"key":"80853_CR13","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1002\/cncr.22904","volume":"110","author":"V Launay-Vacher","year":"2007","unstructured":"Launay-Vacher, V. et al. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: The renal insufficiency and anticancer medications (IRMA) study. Cancer 110, 1376\u20131384. https:\/\/doi.org\/10.1002\/cncr.22904 (2007).","journal-title":"Cancer"},{"key":"80853_CR14","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/j.1523-1755.2004.00720.x","volume":"66","author":"T Ludwig","year":"2004","unstructured":"Ludwig, T., Riethmuller, C., Gekle, M., Schwerdt, G. & Oberleithner, H. Nephrotoxicity of platinum complexes is related to basolateral organic cation transport. Kidney Int. 66, 196\u2013202. https:\/\/doi.org\/10.1111\/j.1523-1755.2004.00720.x (2004).","journal-title":"Kidney Int."},{"key":"80853_CR15","doi-asserted-by":"publisher","first-page":"14298","DOI":"10.1073\/pnas.162491399","volume":"99","author":"S Ishida","year":"2002","unstructured":"Ishida, S., Lee, J., Thiele, D. J. & Herskowitz, I. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc. Natl. Acad. Sci. USA. 99, 14298\u201314302. https:\/\/doi.org\/10.1073\/pnas.162491399 (2002).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"80853_CR16","first-page":"1312","volume":"60","author":"M Komatsu","year":"2000","unstructured":"Komatsu, M. et al. Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Can. Res. 60, 1312\u20131316 (2000).","journal-title":"Can. Res."},{"key":"80853_CR17","first-page":"5853","volume":"9","author":"G Samimi","year":"2003","unstructured":"Samimi, G. et al. Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients. Clin. Cancer Res. 9, 5853\u20135859 (2003).","journal-title":"Clin. Cancer Res."},{"key":"80853_CR18","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.lungcan.2015.05.005","volume":"89","author":"M Sassier","year":"2015","unstructured":"Sassier, M. et al. Renal insufficiency is the leading cause of double maintenance (bevacizumab and pemetrexed) discontinuation for toxicity to advanced non-small cell lung cancer in real world setting. Lung Cancer 89, 161\u2013166. https:\/\/doi.org\/10.1016\/j.lungcan.2015.05.005 (2015).","journal-title":"Lung Cancer"},{"key":"80853_CR19","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","volume":"379","author":"L Horn","year":"2018","unstructured":"Horn, L. et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N. Engl. J. Med. 379, 2220\u20132229. https:\/\/doi.org\/10.1056\/NEJMoa1809064 (2018).","journal-title":"N. Engl. J. Med."},{"key":"80853_CR20","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","volume":"379","author":"L Paz-Ares","year":"2018","unstructured":"Paz-Ares, L. et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N. Engl. J. Med. 379, 2040\u20132051. https:\/\/doi.org\/10.1056\/NEJMoa1810865 (2018).","journal-title":"N. Engl. J. Med."},{"key":"80853_CR21","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski, M. A. et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N. Engl. J. Med. 378, 2288\u20132301. https:\/\/doi.org\/10.1056\/NEJMoa1716948 (2018).","journal-title":"N. Engl. J. Med."},{"key":"80853_CR22","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1093\/ckj\/sfy100","volume":"12","author":"H Izzedine","year":"2019","unstructured":"Izzedine, H. et al. Renal toxicities associated with pembrolizumab. Clin. Kidney J. 12, 81\u201388. https:\/\/doi.org\/10.1093\/ckj\/sfy100 (2019).","journal-title":"Clin. Kidney J."},{"key":"80853_CR23","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/sj.ki.5002697","volume":"73","author":"PL Zhang","year":"2008","unstructured":"Zhang, P. L. et al. Kidney injury molecule-1 expression in transplant biopsies is a sensitive measure of cell injury. Kidney Int. 73, 608\u2013614. https:\/\/doi.org\/10.1038\/sj.ki.5002697 (2008).","journal-title":"Kidney Int."},{"key":"80853_CR24","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1038\/ki.2009.85","volume":"75","author":"K Hosaka","year":"2009","unstructured":"Hosaka, K. et al. Megalin and nonmuscle myosin heavy chain IIA interact with the adaptor protein disabled-2 in proximal tubule cells. Kidney Int. 75, 1308\u20131315. https:\/\/doi.org\/10.1038\/ki.2009.85 (2009).","journal-title":"Kidney Int."},{"key":"80853_CR25","doi-asserted-by":"publisher","first-page":"6698","DOI":"10.1073\/pnas.89.15.6698","volume":"89","author":"RA Orlando","year":"1992","unstructured":"Orlando, R. A., Kerjaschki, D., Kurihara, H., Biemesderfer, D. & Farquhar, M. G. gp330 associates with a 44-kDa protein in the rat kidney to form the Heymann nephritis antigenic complex. Proc. Natl. Acad. Sci. USA. 89, 6698\u20136702. https:\/\/doi.org\/10.1073\/pnas.89.15.6698 (1992).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"80853_CR26","doi-asserted-by":"publisher","first-page":"3935","DOI":"10.1210\/en.2004-0074","volume":"145","author":"H Hama","year":"2004","unstructured":"Hama, H. et al. Evidence indicating that renal tubular metabolism of leptin is mediated by megalin but not by the leptin receptors. Endocrinology 145, 3935\u20133940. https:\/\/doi.org\/10.1210\/en.2004-0074 (2004).","journal-title":"Endocrinology"},{"key":"80853_CR27","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/j.bbrc.2007.04.072","volume":"357","author":"R Kaseda","year":"2007","unstructured":"Kaseda, R. et al. Megalin-mediated endocytosis of cystatin C in proximal tubule cells. Biochem. Biophys. Res. Commun. 357, 1130\u20131134. https:\/\/doi.org\/10.1016\/j.bbrc.2007.04.072 (2007).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"80853_CR28","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda, Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 48, 452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244 (2013).","journal-title":"Bone Marrow Transplant."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-80853-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-80853-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-80853-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T20:59:48Z","timestamp":1670014788000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-80853-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,12]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["80853"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-80853-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,12]]},"assertion":[{"value":"2 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"750"}}